印度制药出口在2024-25年达到30.5B美元,目标是在2030年之前达到130B美元。 India’s pharma exports hit $30.5B in 2024–25, with goals to reach $130B by 2030.

印度的制药出口在2024-25年增长了9.4%,达到304.7亿美元,官员们的目标是到2026-27年实现两位数增长。 India's pharmaceutical exports rose 9.4% in 2024–25 to $30.47 billion, with officials targeting double-digit growth by 2026–27. 该行业估值为600亿美元，预计到2030年将达到1300亿美元，得益于政府举措，如价值100亿卢比的生物制药SHAKTI项目，旨在促进生物制剂和生物类似药的生产。 The sector, valued at $60 billion, is projected to reach $130 billion by 2030, supported by government initiatives like the Rs 10,000 crore Biopharma SHAKTI program to boost biologics and biosimilars production. 印度是世界第三大药品生产国,向200多个国家出口,其中美国和欧洲占出口的34%和19%。 India, the world’s third-largest medicine producer, exports to over 200 countries, with the U.S. and Europe accounting for 34% and 19% of exports. 努力的重点是精简规章、援助中小微企业、加强印度作为全球廉价高质量药品供应商的作用。 Efforts focus on streamlining regulations, aiding MSMEs, and strengthening India’s role as a global supplier of affordable, high-quality medicines.